References of "Stevenaert, Achille"
     in
Bookmark and Share    
Peer Reviewed
See detailDiagnosis of primary thyrotrophin-secreting microadenoma by 1.5 T MR.
Stadnik, T.; Stevenaert, Achille ULg; Beckers, Albert ULg et al

in European Journal of Radiology (1992), 14(1), 18-21

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailLe traitement des prolactinomes par un nouvel agoniste dopaminergique (le CV 205-502) : résultats chez 48 patients.
Beckers, Albert ULg; Ghuysen, A. E.; Abs, R. et al

in Médecine et Hygiène (1992), 50

Detailed reference viewed: 20 (0 ULg)
Peer Reviewed
See detailLes adénomes hypophysaires à TSH.
Beckers, Albert ULg; Stevenaert, Achille ULg

in Revue Française d'Endocrinologie Clinique, Nutrition, et Métabolisme (La) (1992), 33(2), 151-156

Detailed reference viewed: 3 (0 ULg)
See detailEvaluatie van de nieuwe dopamine-agonist CV 205-502 in de behandeling van prolactinomen
Verhelst, J.; Abs, R.; Beckers, Albert ULg et al

in Acta Antwerpiensia (1992), 9

Detailed reference viewed: 13 (0 ULg)
Peer Reviewed
See detailTreatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers, Albert ULg; Petrossians, Patrick ULg; Abs, R. et al

in Journal of Clinical Endocrinology and Metabolism (1992), 75(1), 275-80

Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They ... [more ▼]

Twenty-nine patients with macroprolactinomas were treated by monthly intramuscular injections of the long-acting and repeatable form of bromocriptine (Parlodel-LAR) in doses ranging from 50-150 mg. They were divided into two groups: group I consisted of 22 patients who received Parlodel LAR before transsphenoidal adenomectomy; group II was composed of 7 patients with earlier neurosurgery and of 2 patients from group I not cured by transsphenoidal adenomectomy. Duration of therapy varied from 1-12 months, and a total of 104 injections was given. At nadir day, serum PRL levels were situated between less than 1% and 43% of pretreatment values. At day 28 after the first injection, serum PRL levels varied between less than 1% to 139% of initial values. No difference could be detected between the two groups regarding the percent of PRL inhibition. Long-term treatment with Parlodel-LAR resulted in a sustained inhibition of PRL secretion, except for 1 case. Resumption of menstrual cycles occurred in 4 out of 15 women and correction of hypogonadism in 4 out of 14 men. Amelioration of disturbed visual fields was recorded in 3 out of 8 patients. Diminution of the adenoma volume was radiologically documented in 14 out of 22 cases. Only few and mild side effects were recorded. One patient with partial adrenal deficiency suffered from a syncope, but this was prevented by hydrocortisone supplementation during the subsequent Parlodel-LAR administration. In conclusion, Parlodel-LAR proved effective in the treatment of macroprolactinomas, achieving rapid inhibition of PRL secretion, and in some patients amelioration of hypopituitarism, reduction in tumor size, and improvement in visual fields, and caused no serious side effects. It is a valuable preparation to surgery and can also be used in long-term medical therapy. [less ▲]

Detailed reference viewed: 5 (0 ULg)
See detailClinical experience with CV 205-502 (Sandoz) in the treatment of prolactinomas
mahler, c; verhelst, j; abs, r et al

in ninth Internation Congress of Endocrinology-Abstract book (1992)

Detailed reference viewed: 3 (0 ULg)
See detailThyrotorpin-secreting pituitary adenomas - Report of 8 cases.
Stevenaert, Achille ULg; Abs, R.; Mahler, Ch. et al

Conference (1992)

Detailed reference viewed: 5 (0 ULg)
See detailThyrotropin-secreting pituitary adenomas. Report of 8 cases.
Beckers, Albert ULg; Abs, R.; Mahler, Ch. et al

Conference (1992)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailMR of radiation induced myelopathy.
Collignon, F.; Flandroy, P.; Martin, Didier ULg et al

Conference (1991, October 06)

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailEffect of treatment with octreotide on the morphology of growth hormone secreting pituitary adenomas : study of 24 cases.
Beckers, Albert ULg; Kovacs, K.; Horvwarth, E. et al

in Endocrine Pathology (1991), 2(3), 123-131

Twenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal surgery. Radiological ... [more ▼]

Twenty-four acromegalic patients were treated with octreotide subcutaneously for periods of 3 to 6 weeks (group I, 12 cases) or 6 months (group II, 12 cases) before transsphenoidal surgery. Radiological studies performed in 19 patients before and at the end of this treatment period revealed no changes in 8 cases. In 8 other cases, a slight reduction in tumorsize was observed, and in 3 cases an important shrinkage was documented. At surgery, the adenomatous tissue appeared softer than in nonpretreated patients, facilitating the operation. Pathological examination revealed widening of perivascular spaces with accumulation of fibrous tissue and more crinophagy than in nonpretreated patients but failed to reveal morphologically pronounced cell involution as observed in prolactin-producing adenomas treated with dopamine agonists. No significant difference in frequency or extent of cellular changes was noted between the two groups. These morphological findings seem to be more consistent with a functional inhibition of growth hormone release than with cellular alterations induced by octreotide. [less ▲]

Detailed reference viewed: 3 (0 ULg)
Peer Reviewed
See detailCyclical Cushing's disease : a case report.
Velkeniers, B.; Beckers, Albert ULg; Stevenaert, Achille ULg et al

in Pathology - Research & Practice (1991), 187(5), 603-607

A 41-year-old man with clinical Cushing's syndrome and intermittent central ACTH hypersecretion for a period of 9 1/2 years follow-up is described. Episodes of biochemical and clinical remission ... [more ▼]

A 41-year-old man with clinical Cushing's syndrome and intermittent central ACTH hypersecretion for a period of 9 1/2 years follow-up is described. Episodes of biochemical and clinical remission alternated with periods of florid Cushing's disease, characterized by circadian hyperpulsatile ACTH and cortisol secretion. Responses to metyrapone and inhibition of ACTH and cortisol hypersecretion after high dose dexamethasone during active phases of the disease favored a central origin of ACTH hypersecretion, confirmed by simultaneous bilateral venous sampling of the sinus petrosus inferior. Prolonged clinical remission followed near total anterior hypophysectomy. However, on anatomopathological examination of the pituitary neither corticotroph cell hyperplasia nor a microadenoma could be documented. The possibility of a functional ACTH hypersecretion is discussed. [less ▲]

Detailed reference viewed: 27 (2 ULg)
Peer Reviewed
See detailAdenohypophysis hormone gene products in 14 pituitary adenomas: analysis by immunohistochemistry and northern blotting.
Scippo, Marie-Louise ULg; Beckers, Albert ULg; Frankenne, Francis ULg et al

in Archives Internationales de Physiologie, de Biochimie et de Biophysique (1991), 99(2), 135-140

We investigated 14 pituitary adenomas (10 silent adenomas; 3 prolactinomas and one GH-secreting tumor) for the presence of hormone gene transcripts (Northern blot) as well as for translation products ... [more ▼]

We investigated 14 pituitary adenomas (10 silent adenomas; 3 prolactinomas and one GH-secreting tumor) for the presence of hormone gene transcripts (Northern blot) as well as for translation products (immunohistochemistry). The GH-secreting tumor was shown to express the genes coding for GH and PRL and to synthesize the corresponding hormones. In the cases of prolactinomas, immunohistochemical data demonstrated the synthesis of prolactin only. In addition to the PRL gene, Northern blot analysis revealed the transcription of the alpha-subunit gene in one case. Hormone genes were found to be expressed in 7 out of the 10 silent tumors, whereas no hormone synthesis was detected in any of these tissues. LH-beta mRNA was found in 3 cases, FSH-beta mRNA in 5 cases and alpha-subunit gene was shown to be expressed in one case. Surprisingly, the level of expression of the FSH-beta-gene was higher than in normal tissue. This study confirms that some so called << silent >> adenomas are expressing alpha- and/or beta-subunit glycoprotein hormone genes, even if no hormone is synthesized. The therapeutic action of bromocriptine described in some << silent >> adenomas cases could be related to that hormone gene expression potentiality. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailThyrotropin-Secreting Pituitary Adenomas: Report of Seven Cases
Beckers, Albert ULg; Abs, R.; Mahler, C. et al

in Journal of Clinical Endocrinology and Metabolism (1991), 72(2), 477-83

Seven patients with hyperthyroidism due to a TSH-secreting pituitary macroadenoma have been observed of a total of 800 patients with pituitary tumors over a period of 15 yr. Serum TSH levels varied ... [more ▼]

Seven patients with hyperthyroidism due to a TSH-secreting pituitary macroadenoma have been observed of a total of 800 patients with pituitary tumors over a period of 15 yr. Serum TSH levels varied between 1.1-36.3 mU/L. The serum alpha-subunit level was low in 1 case, while in 4 other cases the concentration was elevated and varied between 3.7-7.8 micrograms/L. Serum TSH beta levels were normal in the 4 cases in which it was determined. Serum GH or PRL levels were elevated in 5 cases. In 1 patient the cosecretion of TSH, GH, and PRL was confirmed by immunocytochemical examination. Serum TSH and alpha-subunit responses to TRH, GnRH, CRF, GRF, dexamethasone, methimazole, T3, and bromocriptine administration were variable when studied. Serum TSH and alpha-subunit circadian rhythms were absent in 1 case and inverted in another. A serum alpha-subunit pulsatility without TSH pulses was observed in 1 patient. Five patients underwent transsphenoidal adenomectomy. Three of 4 patients operated on in our center were cured, but a recurrence of the adenoma was found in 1 of them after 5 yr. The fifth patient was not cured. Treatment with octreotide in 3 patients resulted in normalization of serum TSH, GH, and thyroid hormones levels. Cosecretion of PRL in 1 case and alpha-subunit in 2 cases was also inhibited. Partial tachyphylaxis occurred in 1 patient. In summary, heterogeneity in clinical presentation, hormonal expression, and therapeutic response appears to characterize these TSH-secreting adenomas. [less ▲]

Detailed reference viewed: 60 (0 ULg)